Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Monoclonal Antibody Blocks B-Cell Receptor and Eases Leukemia Burden in Mouse Model

By BiotechDaily International staff writers
Posted on 26 May 2014
Blocking the B-cell-activating factor receptor (BAFF-R) on leukemia cells has been suggested as a new approach for treating an acute, chemotherapy-resistant form of childhood leukemia.

Acute lymphoblastic leukemia (ALL) is characterized by an excessive amount of white blood cell precursors (B-cell lymphoblasts) in the blood and bone marrow. B-cell lineage ALL (pre-B ALL) accounts for 80% to 85% of childhood ALL.

BAFF-R is encoded in humans by the TNFRSF13C (tumor necrosis factor receptor superfamily member 13C) gene. BAFF enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in their serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by the TNFRSF13C gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain.

It is thought that BAFF-R is the principal receptor required for BAFF-mediated mature B-cell survival. Since BAFF-R is expressed on precursor pre-B ALL cells but not on their pre-B normal counterparts, selective killing of ALL cells is possible by targeting this receptor.

Investigators at the University of Southern California (USA) tested a novel humanized anti–BAFF-R monoclonal antibody in a study carried out on leukemia cell cultures and in an immunodeficient mouse transplant model.

They reported in the May 13, 2014, online edition of the journal Molecular Cancer Therapeutics that the antibodies significantly stimulated natural killer cell-mediated killing of different human patient-derived ALL cells. Moreover, incubation of such ALL cells with these antibodies stimulated phagocytosis by macrophages. When this was tested in the immunodeficient transplant model, mice that were treated with the antibody had a significantly decreased leukemia burden in bone marrow and spleen.

"We have now demonstrated that BAFF-R is a strong potential therapeutic target for treating chemotherapy-resistant leukemia cells, without damaging healthy cells," said senior author Dr. Nora Heisterkamp, professor of research, pediatrics, and pathology at the University of Southern California. "We found that human pre-B ALL cells could be even further reduced when the anti-BAFF-R antibody was combined with chemotherapy or another therapeutic agent. We are looking at a potential one, two punch."

Related Links:

University of Southern California



Channels

Genomics/Proteomics

view channel
Image: Nomarski interference contrast photomicrographs of Cryptosporidium in the feces of an HIV-positive human (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).

Advanced Genetic Tools Revamp Search for Drugs to Treat Cryptosporidium

Genetically engineered modifications to genome of the diarrhea-causing parasite Cryptosporidium are expected to expedite research towards vaccine and drug development to prevent or cure infection by this pathogen.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.